No 1: Progress in Sarcoma Management

4 Bone Sarcoma ... Turning the Corner
Samuel V. Agresta, MD, MPH & TM

7 Practical Issues of Intraoperative Frozen Section Diagnosis of Bone and Soft Tissue Lesions
Marilyn M. Bui, MD, PhD, Prudence Smith, MD, Samuel V. Agresta, MD, MPH & TM, David Cheong, MD, and G. Douglas Letson, MD

13 Orthopedic Surgery Options for the Treatment of Primary Osteosarcoma
German A. Marulanda, MD, Eric R. Henderson, MD, David A. Johnson, PA-C, G. Douglas Letson, MD, and David Cheong, MD

21 Advanced-Technology Radiation Therapy for Bone Sarcomas
Samir Patel, MD, and Thomas F. DeLaney, MD

38 Outpatient Chemotherapy Plus Radiotherapy in Sarcomas: Improving Cancer Control With Radiosensitizing Agents
Pete Anderson, MD, PhD, Dolly Aguiera, MD, Margaret Pearson, CNP, and Shaio Woo, MD

47 Therapeutic Potential of Directed Tyrosine Kinase Inhibitor Therapy in Sarcomas
Audrey C. Shor, PhD, MPH, Samuel V. Agresta, MD, MPH & TM, Gina Z. D’Amato, MD, and Vernon K. Sondak, MD

55 Current Issues in Adolescent and Young Adult Cancer Survivorship
Hatem Soliman, MD, and Samuel V. Agresta, MD, MPH & TM

63 Cultural Values and Secondary Prevention of Breast Cancer in African American Women
Ellen Burke Beckjord, PhD, MPH, and Ann C. Klassen, PhD

72 Colorectal Cancer Screening and African Americans: Findings From a Qualitative Study
Richard C. Palmer, DrPH, Lynn A. Midgette, MPH, and Irene Dankwa, MD, MPH

80 Transcatheter Arterial Chemoembolization and Percutaneous Ethanol Injection for Hepatocellular Carcinoma: A Retrospective Review of the Veterans Affairs Caribbean Healthcare System
Jessica Narvaez-Lugo, MD, William W. Cáceres, MD, FACP, Doris H. Toro, MD, FACP, Manuel R. Pérez-González, MD, Alvin A. Almodovar, MD, Awilda M. Maldonado-Mercado, MD, FACCP, Norma Salgado, MD, and Gerant M. Rivera-Santeliz, MD

120 Cardiac Mortality and Morbidity After Breast Cancer Treatment
Eleanor E. R. Harris, MD

130 Molecular Analysis-Based Treatment Strategies for Non–Small Cell Lung Cancer
Gerald Bepler, MD, PhD, Mubeena Begum, MBBS, MSPH, and George R. Simon, MD, FACP, FCCP

140 The Use of Blood Biomarkers to Predict Radiation Lung Toxicity: A Potential Strategy to Individualize Thoracic Radiation Therapy
Fang-Ming (Spring) Kong, MD, PhD, MPH, Xiaoping Ao, PhD, Li Wang, MD, PhD, and Theodore S. Lawrence, MD, PhD

151 Predicting Response to Clinical Radiotherapy: Past, Present, and Future Directions
Javier F. Torres-Roca, MD, and Craig W. Stevens, MD, PhD

157 Barriers and Facilitators for Colorectal Cancer Screening Practices in the Latino Community: Perspectives From Community Leaders
Ana Natale-Pereira, MD, MPH, Jonnie Marks, PhD, Marios Vega, RN, BSN, Dwayne Mouzon, MPH, Shanna V. Hudson, PhD, and Debbie Salas-Lopez, MD, MPH

166 Apsaalooke Women’s Experiences With Pap Test Screening
Adina J. Smith, PhD, Suzanne Christopher, PhD, Victoria R. LaFromboise, MS, Bethany L. Letiecq, PhD, and Alma Knows His Gun McCormick

174 Colorectal Cancer Screening Practices of Primary Care Physicians in Washington State
Peggy A. Hannon, PhD, MPH, Diane P. Martin, PhD, Jeffrey R. Harris, MD, MPH, MBA, and Deborah J. Bowen, PhD

No 2: Personalized Treatment Approaches in Radiation Oncology

100 Personalized Treatment Approaches in Radiation Oncology: The Future Is Now
Eleanor E. R. Harris, MD, and Craig W. Stevens, MD, PhD

104 Stereotactic Body Radiation Therapy: Transcending the Conventional to Improve Outcomes
Thomas J. Dilling, MD, and Sarah E. Holfte, MD

112 Functional Lung Imaging in Thoracic Cancer Radiotherapy
Geoffrey Zhang, PhD, Thomas J. Dilling, MD, Craig W. Stevens, MD, PhD, and Kenneth M. Forster, PhD

125 Therapy for Unresectable Recurrent and In-Transit Extremity Melanoma
Mark I. Gimbel, MD, Keith A. Delman, MD, and Jonathan S. Zager, MD

223 Radiation Therapy as Primary and Adjuvant Treatment for Local and Regional Melanoma
Lawrence B. Berk, MD, PhD

No 3: Melanoma

192 Melanoma: Promising New Discoveries and Treatment Modalities for Difficult Clinical Scenarios
Jonathan S. Zager, MD, and Adil I. Daud, MD

196 Activated Stat-3 in Melanoma
Jane L. Messina, MD, Hua Yu, PhD, Adam I. Riker, MD, FACS, Pamela N. Munster, MD, Richard L. Jove, PhD, and Adil I. Daud, MD

202 The Impact of Genomics in Understanding Human Melanoma Progression and Metastasis
Suping Ren, MD, PhD, Suhu Liu, MD, PhD, Steven A. Enkemann, MS, PhD, Jingfang Ju, PhD, and Adam I. Riker, MD, FACS

216 Surgical Management of Melanoma In Situ on Chronically Sun-Damaged Skin
Graham S. Clark, MD, Efi Ch. Pappas-Politis, MD, Basil S. Cherpelis, MD, Jane L. Messina, MD, Meckar G. Möller, MD, C. Wayne Cruse, MD, and L. Frank Glass, MD

225 Therapy for Unresectable Recurrent and In-Transit Extremity Melanoma
Mark I. Gimbel, MD, Keith A. Delman, MD, and Jonathan S. Zager, MD

233 Radiation Therapy as Primary and Adjuvant Treatment for Local and Regional Melanoma
Lawrence B. Berk, MD, PhD
No 4: Pancreatic Cancer

276 New Insights and Gains in Pancreatic Cancer
Mokenge P. Malafa, MD

280 Early Detection of Pancreatic Cancer: Why, Who, and How to Screen
Jason Klapman, MD, and Mokenge P. Malafa, MD

288 Outcomes Following Resection of Pancreatic Adenocarcinoma: 20-Year Experience at a Single Institution
James F. Helm, MD, PhD, Barbara A. Centeno, MD, Domenico Coppola, MD, Mihaela Druta, MD, Jong Y. Park, PhD, Dung-Tsa Chen, PhD, Pamela J. Hodul, MD, Larry K. Kvol, MD, Timothy J. Yeatman, MD, Larry C. Carey, MD, Richard C. Karl, MD, and Mokenge P. Malafa, MD

295 Borderline Resectable Pancreatic Cancer: On the Edge of Survival
Gregory M. Springett, MD, PhD, and Sarah E. Hoffe, MD

308 Cancer of the Pancreas: Are We Making Progress? A Review of Studies in the US Oncology Research Network
Thomas Cartwright, MD, Donald A. Richards, MD, PhD, and Kristi A. Boehm, MS

314 Aggressive Surgical Resection in the Management of Pancreatic Neuroendocrine Tumors: When Is It Indicated?
Pamela J. Hodul, MD, Jonathan R. Strosberg, MD, and Larry K. Kvol, MD

322 Interdisciplinary Management of an Intraductal Papillary Mucinous Neoplasm of the Pancreas
Rajesh M. Nair, MD, James S. Barthel, MD, Barbara A. Centeno, MD, Junsung Choi, MD, Jason B. Klapman, MD, and Mokenge P. Malafa, MD

334 Willingness to Participate in Cancer Screenings: Blacks vs Whites vs Puerto Rican Hispanics
Ralph V. Katz, DMD, MPH, PhD, Nancy R. Kressin, PhD, B. Lee Green, PhD, Min Qi Wang, PhD, and Stefanie Louise Russell, DDS, MPH, PhD

344 Participation in Biomedical Research Studies and Cancer Screenings: Perceptions of Risks to Minorities Compared With Whites
Ralph V. Katz, DMD, MPH, PhD, Min Qi Wang, PhD, B. Lee Green, PhD, Nancy R. Kressin, PhD, Cristina Claudio, PhD, and Christelle Sommervil, MPH, MS, CCRP

352 Management of Nerve Sheath Tumors ARISING in the Sympathetic Chain
Surbhi Jain, MD, Kristin Houseknecht, MPH, Amyn M. Rojiani, MD, PhD, Matthias Setzer, MD, and Frank D. Vrionis, MD, MPH, PhD

No. 4 Supplement 2008:
Myelodysplastic Syndromes:
Present Status and New Avenues to Optimize Clinical Outcome

2 Challenges in Myelodysplastic Syndromes: Raising Awareness and Promoting New Insight in Therapeutic Options
Alan F. List, MD

4 Myelodysplastic Syndromes: Diagnosis and Staging
Luca Malcovati, MD, and Stephen D. Nimer, MD

14 Changing the Treatment Paradigm in Myelodysplastic Syndromes
Ghulam Mufti, MB, DM, FRCP, FRCPath, and Tara L. Chen, PharmD

29 Treatment Strategies to Optimize Clinical Benefit in the Patient With Myelodysplastic Syndromes
Alan F. List, MD

40 Future Directions in Myelodysplastic Syndrome: Newer Agents and the Role of Combination Approaches
Steven D. Gore, MD, and Evelyn R. Hermes-DeSantis, PharmD, BCPS